We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ATCC Licenses CRISPR/CAS9 Technology from the Broad Institute

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "ATCC Licenses CRISPR/CAS9 Technology from the Broad Institute"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

ATCC, the premier global biological materials resource and standards organization, announces that it has licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard. ATCC plans to use the gene editing technology to develop a portfolio of new products and services to support basic and translational research.

CRISPR gene editing allows for precise genetic modifications. This capability allows researchers to create more relevant and predictable in vitro disease models, which will enable a greater level of success in drug discovery, development, and screening.

“The rapid growth of CRISPR/Cas9 applications provides a perfect environment for ATCC to leverage our comprehensive portfolio of cells, microorganisms, and services to meet the unmet demands of global researchers to support their scientific discoveries. Licensing the CRISPR/Cas9 technology from the Broad Institute allows ATCC scientists to unlock the full potential of our unique portfolio for creating standards for basic and translational research,” stated Mindy Goldsborough, Ph.D., Vice President & General Manger, ATCC Cell Systems. “We will build on the high quality and standards that researchers have expected from ATCC over the past 90 years.”

The first ATCC product developed using the licensed technology is the EML4-ALK Fusion-A549 Isogenic Cell Line (ATCC® CCL-185IG™). This cell line was derived from the parental A549 non-small cell lung cancer cell line, which is known as a work horse for in vitro and in vivo lung cancer research. The EML4-ALK Fusion mutation is critical for drug discovery and molecular diagnostics of non-small cell lung cancer. EML4-ALK Fusion-A549 Isogenic Cell Line has been intensively validated on the genomic, transcript, and protein level, and is otherwise identical to the parental line. This isogenic cell line is more sensitive to ALK inhibitor crizotinib when compared to A549, and serves as a vital model to study cell signaling pathways in cancer as well as in drug screening. EML4-ALK Fusion-A549 Isogenic Cell Line became available in mid-January 2016.